Terns Pharmaceuticals/$TERN

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Terns Pharmaceuticals

Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases. Its product candidates include TERN-701, TERN-601, TERN-501 and TERN-800.

Ticker

$TERN
Sector
Health Care
Primary listing
NASDAQ

Industry

Pharmaceuticals
Headquarters
Foster City, United States

Employees

59

ISIN

US8808811074
Website
www.ternspharma.com

TERN Metrics

BasicAdvanced
$489M
-
-$1.08
-0.17
-

What the Analysts think about TERN

Analyst ratings (Buy, Hold, Sell) for Terns Pharmaceuticals stock.

Bulls say / Bears say

Terns Pharmaceuticals has reported positive interim results from its Phase 1 CARDINAL study of TERN-701, indicating promising molecular responses and a favorable safety profile, with dose expansion planned for the first half of 2025. (Investing.com)
The company successfully completed an upsized public offering, raising approximately $150.15 million to fund the development of key product candidates, including TERN-701 and TERN-601. (Yahoo Finance)
Analysts have maintained an 'Outperform' rating for Terns Pharmaceuticals, citing the potential of TERN-701 for Chronic Myeloid Leukemia as a key catalyst, with price targets raised to $20.00. (Investing.com)
Terns Pharmaceuticals' stock has experienced significant volatility, hitting a 52-week low of $3.27 in March 2025, reflecting a 54% decline from its 52-week high of $11.40. (Investing.com)
The company faces intense competition in the obesity treatment market, with Eli Lilly's retatrutide demonstrating a mean weight reduction of up to 24.2% at 48 weeks, potentially overshadowing Terns' TERN-601. (Markets Insider)
Recent insider selling, including CFO Mark J. Vignola's sale of 9,059 shares in January 2025, may raise concerns about internal confidence in the company's future performance. (Defense World)
Data summarised monthly by Lightyear AI. Last updated on 12 Jul 2025.

TERN Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

TERN Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-

TERN News

AllArticlesVideos
Terns Pharmaceuticals Presents Positive Data from Phase 1 Study of TERN-601 Once-daily Oral GLP-1R Agonist for Treatment of Obesity at 85th Annual American Diabetes Association Scientific Sessions

Terns Pharmaceuticals Presents Positive Data from Phase 1 Study of TERN-601 Once-daily Oral GLP-1R Agonist for Treatment of Obesity at 85th Annual American Diabetes Association Scientific Sessions

GlobeNewsWire·4 weeks ago
3 Penny Stocks Wall Street Sees With 243% Upside

3 Penny Stocks Wall Street Sees With 243% Upside

24/7 Wall Street·1 month ago
Terns Pharmaceuticals to Participate in Upcoming June Investor Conferences

Terns Pharmaceuticals to Participate in Upcoming June Investor Conferences

GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $TERN

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs